Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TILs with Chemoradiotherapy in Nasopharyngeal Carcinoma
NCT02421640Phase 2Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Mar 2015
- Primary completion
- Mar 2017
- Modality
- Monoclonal Antibodies, Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of GC101 TIL + pembrolizumab in nasopharyngeal carcinoma (NPC), sponsored by Sun Yat-sen University. Status: unknown.
02
Drugs
GC101 TIL + pembrolizumab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT02421640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02421640.